Compare SMID & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMID | EQ |
|---|---|---|
| Founded | 1960 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.6M | 151.5M |
| IPO Year | 1996 | 2018 |
| Metric | SMID | EQ |
|---|---|---|
| Price | $25.80 | $2.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 11.3K | ★ 423.3K |
| Earning Date | 04-14-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.76 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $93,446,000.00 | $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $51.75 | ★ N/A |
| Revenue Growth | ★ 19.03 | N/A |
| 52 Week Low | $24.63 | $0.76 |
| 52 Week High | $43.00 | $3.54 |
| Indicator | SMID | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 43.29 | 44.14 |
| Support Level | $25.11 | $2.15 |
| Resistance Level | $31.47 | $2.58 |
| Average True Range (ATR) | 1.26 | 0.16 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 37.56 | 10.00 |
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.